Holen Sie sich die Stockscreener-App
3.53
11.01%
0.35
Handel nachbörslich:
3.38
-0.15
-4.25%
Schlusskurs vom Vortag:
$3.18
Offen:
$3.12
24-Stunden-Volumen:
1.90M
Relative Volume:
2.14
Marktkapitalisierung:
$14.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.79M
KGV:
-0.5708
EPS:
-6.1838
Netto-Cashflow:
$-23.12M
1W Leistung:
+37.92%
1M Leistung:
+30.26%
6M Leistung:
+2.92%
1J Leistung:
+1,366%
1-Tages-Spanne:
$2.91
$3.62
1-Wochen-Bereich:
$2.52
$4.70
52-Wochen-Spanne:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.53 | 13.48M | 0 | -21.79M | -23.12M | -6.1838 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
SEC Form 424B5 filed by Cellectar Biosciences Inc. - Quantisnow
What's Going With Cellectar Biosciences Stock On Wednesday? - Benzinga
Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus - TechStock²
Crude Oil Down 4%; PayPal Shares Fall After Q1 Results - Benzinga
CLRB Stock Surges 28.6% on $140M Financing and Positive Trial Data - Meyka
Cellectar Biosciences announces up to $140M financing deal; shares surge - MSN
Dow Jumps Over 300 Points; Tyson Foods Posts Upbeat Earnings - Benzinga
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million - Investing News Network
Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia - Yahoo Finance
CLRB Stock Pops As New Cancer Trial Sparks Trading Interest - StocksToTrade
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses - Benzinga
Cellectar Biosciences raises up to $140 million in financing By Investing.com - Investing.com South Africa
CLRB Stock Jumps As New Breast Cancer Trial Begins - timothysykes.com
Cellectar reports 12-month data for WM treatment trial - Investing.com
Cellectar reports 12-month data for WM treatment trial By Investing.com - Investing.com Canada
Cancer drug posts 17.8-month responses after four 30-minute infusions - Stock Titan
Cellectar Biosciences Inc. (CLRB) has successfully completed a financing round, led by Nantahala Capital Management, LLC. - Exchange Bitget
Cellectar Biosciences raises up to $140 million in financing - Investing.com
Cellectar Biosciences stock soars 130% on $140M financing By Investing.com - Investing.com Australia
Cellectar Biosciences Reports Positive 12-Month Follow-Up - GlobeNewswire
Cellectar Biosciences stock soars 130% on $140M financing - Investing.com
Cellectar lines up $140M to fund cancer drug study and FDA filing - Stock Titan
MSN - MSN
Cellectar Biosciences (CLRB) price target decreased by 59.62% to 14.28 - MSN
MSN Money - MSN
Cellectar BioSciences | 10-K/A: Annual report (Amendment) - Moomoo
Cellectar Biosciences (NASDAQ: CLRB) details governance, ownership and financings in 10-K/A - Stock Titan
CLRB Price Today: Cellectar Biosciences INC NEW Stock Price, Quote & Chart | MEXC - MEXC Exchange
CLRB (Cellectar Biosciences Inc.) reports narrower than expected Q4 2025 loss, yet shares drop nearly 3 percent.High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Cellectar to present WM treatment data at oncology meeting By Investing.com - Investing.com Australia
Cellectar to present WM treatment data at oncology meeting - Investing.com
Cellectar Biosciences, Inc. Announces Acceptance of Abstract for Presentation on Iopofosine I-131 at ASCO Annual Meeting - Quiver Quantitative
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 - marketscreener.com
Cellectar takes cancer-drug data to ASCO for patients with no approved therapy - Stock Titan
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences (CLRB) Begins Phase 1b Trial for Triple Ne - GuruFocus
Cellectar enrolls first patient in phase 1b cancer trial By Investing.com - Investing.com South Africa
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Triple Negative Breast Cancer - National Today
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer - National Today
Cellectar enrolls first patient in phase 1b cancer trial - Investing.com
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) - The Manila Times
First patient joins Cellectar study for hard-to-treat breast cancer - Stock Titan
Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer - Intellectia AI
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Aug Mood: Can Cellectar Biosciences Inc weather a recession2026 PostEarnings & Entry Point Strategy Guides - baoquankhu1.vn
CEO Moves: Is Cellectar Biosciences Inc a top pick in the sectorIPO Watch & Weekly Top Performers Watchlists - baoquankhu1.vn
Growth Value: Will Cellectar Biosciences Inc stock benefit from M AQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Trading Action: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Buybacks Report: How does Cellectar Biosciences Inc compare to its peersQuarterly Portfolio Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):